DK175799B1 - Fremgangsmåde til præservering og fremgangsmåde til fremstilling af liposomer samt en lyophiliseret sammensætning og en præserveret sammensætning - Google Patents
Fremgangsmåde til præservering og fremgangsmåde til fremstilling af liposomer samt en lyophiliseret sammensætning og en præserveret sammensætning Download PDFInfo
- Publication number
- DK175799B1 DK175799B1 DK198604283A DK428386A DK175799B1 DK 175799 B1 DK175799 B1 DK 175799B1 DK 198604283 A DK198604283 A DK 198604283A DK 428386 A DK428386 A DK 428386A DK 175799 B1 DK175799 B1 DK 175799B1
- Authority
- DK
- Denmark
- Prior art keywords
- liposomes
- trehalose
- initial
- lyophilisates
- lipid
- Prior art date
Links
- 239000002502 liposome Substances 0.000 title claims description 63
- 238000000034 method Methods 0.000 title claims description 36
- 239000000203 mixture Substances 0.000 title claims description 25
- 238000002360 preparation method Methods 0.000 title claims description 14
- 238000004321 preservation Methods 0.000 title description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 45
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 45
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 42
- 150000002632 lipids Chemical class 0.000 claims description 32
- 239000000463 material Substances 0.000 claims description 25
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 17
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 17
- 239000012528 membrane Substances 0.000 claims description 15
- 229930006000 Sucrose Natural products 0.000 claims description 14
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 14
- 239000005720 sucrose Substances 0.000 claims description 14
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 235000014633 carbohydrates Nutrition 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 150000001720 carbohydrates Chemical class 0.000 claims description 8
- 150000002016 disaccharides Chemical class 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229940041181 antineoplastic drug Drugs 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 229940039227 diagnostic agent Drugs 0.000 claims description 3
- 239000000032 diagnostic agent Substances 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 229920002521 macromolecule Polymers 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 229940127230 sympathomimetic drug Drugs 0.000 claims description 2
- 239000003124 biologic agent Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 230000000304 vasodilatating effect Effects 0.000 claims 1
- 239000002691 unilamellar liposome Substances 0.000 description 17
- 238000004108 freeze drying Methods 0.000 description 16
- 239000000523 sample Substances 0.000 description 16
- ODBLHEXUDAPZAU-UHFFFAOYSA-N threo-D-isocitric acid Natural products OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 9
- 150000003904 phospholipids Chemical class 0.000 description 8
- ODBLHEXUDAPZAU-ZAFYKAAXSA-N D-threo-isocitric acid Chemical compound OC(=O)[C@H](O)[C@@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-ZAFYKAAXSA-N 0.000 description 6
- ODBLHEXUDAPZAU-FONMRSAGSA-N Isocitric acid Natural products OC(=O)[C@@H](O)[C@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-FONMRSAGSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 3
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- -1 phospatidylserine Chemical compound 0.000 description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 description 2
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000002165 resonance energy transfer Methods 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- BALXUFOVQVENIU-GNAZCLTHSA-N Ephedrine hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-GNAZCLTHSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 229940008238 amphetamine sulfate Drugs 0.000 description 1
- PYHRZPFZZDCOPH-UHFFFAOYSA-N amphetamine sulfate Chemical compound OS(O)(=O)=O.CC(N)CC1=CC=CC=C1.CC(N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-UHFFFAOYSA-N 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 229960002534 ephedrine hydrochloride Drugs 0.000 description 1
- 229960003072 epinephrine hydrochloride Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 108010051201 lipid I Proteins 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- UYDLBVPAAFVANX-UHFFFAOYSA-N octylphenoxy polyethoxyethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCO)C=C1 UYDLBVPAAFVANX-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/227—Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Acoustics & Sound (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69067985A | 1985-01-11 | 1985-01-11 | |
| US69067985 | 1985-01-11 | ||
| PCT/US1986/000016 WO1986003938A1 (fr) | 1985-01-11 | 1986-01-08 | Procede de conservation de liposomes |
| US8600016 | 1986-01-08 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK428386D0 DK428386D0 (da) | 1986-09-08 |
| DK428386A DK428386A (da) | 1986-11-11 |
| DK175799B1 true DK175799B1 (da) | 2005-02-28 |
Family
ID=24773483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK198604283A DK175799B1 (da) | 1985-01-11 | 1986-09-08 | Fremgangsmåde til præservering og fremgangsmåde til fremstilling af liposomer samt en lyophiliseret sammensætning og en præserveret sammensætning |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0208764A4 (fr) |
| JP (1) | JPS62501631A (fr) |
| AU (1) | AU587600B2 (fr) |
| CA (1) | CA1275248C (fr) |
| DK (1) | DK175799B1 (fr) |
| WO (1) | WO1986003938A1 (fr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1260393A (fr) * | 1984-10-16 | 1989-09-26 | Lajos Tarcsay | Liposomes de lipides synthetiques |
| US5484432A (en) * | 1985-09-27 | 1996-01-16 | Laser Biotech, Inc. | Collagen treatment apparatus |
| GB8604983D0 (en) * | 1986-02-28 | 1986-04-09 | Biocompatibles Ltd | Protein preservation |
| WO1988006441A1 (fr) * | 1987-02-23 | 1988-09-07 | Vestar, Inc. | Deshydratation de preparations vesiculaires pour stockage a longterme |
| ATE107502T1 (de) * | 1988-10-05 | 1994-07-15 | Vestar Inc | Verfahren zur herstellung von liposomen mit verbesserter stabilität während des trocknens. |
| US6007817A (en) | 1988-10-11 | 1999-12-28 | University Of Southern California | Vasopermeability enhancing immunoconjugates |
| IL91933A (en) * | 1988-10-11 | 1994-12-29 | Univ Southern California | Their immuno-bracelet and isophiles which are beneficial in increasing vascular permeability or blood supply to tumor or otherwise damaged tissue |
| US5059518A (en) * | 1988-10-20 | 1991-10-22 | Coulter Corporation | Stabilized lyophilized mammalian cells and method of making same |
| GB9111611D0 (en) | 1991-05-30 | 1991-07-24 | Sandoz Ltd | Liposomes |
| DE69233119T2 (de) * | 1991-06-18 | 2004-05-13 | Imarx Pharmaceutical Corp., Tucson | Neue liposomale arzneimittelfreisetzungssysteme |
| JP3187622B2 (ja) | 1993-10-07 | 2001-07-11 | カネボウ株式会社 | リポソーム |
| AU2215995A (en) * | 1994-04-07 | 1995-10-30 | Akzo Nobel N.V. | Freeze-dried compositions comprising rna |
| DK0967862T3 (da) * | 1997-02-07 | 2003-05-12 | Elan Drug Delivery Ltd | Fremgangsmåde og præparater til fremstilling af tørrede, lagringsstabile blodplader |
| GB9813100D0 (en) * | 1998-06-18 | 1998-08-19 | Secr Defence | Method of forming liposomes |
| US6710038B1 (en) | 1999-12-14 | 2004-03-23 | Kibun Food Chemifa Co., Ltd. | Emulsification method using propylene glycol hyaluronate |
| EP1255439A4 (fr) | 2000-02-10 | 2007-01-03 | Univ California | Plaquettes et procedes therapeutiques |
| US6770478B2 (en) | 2000-02-10 | 2004-08-03 | The Regents Of The University Of California | Erythrocytic cells and method for preserving cells |
| PL363618A1 (en) * | 2000-11-09 | 2004-11-29 | Neopharm, Inc. | Sn-38 lipid complexes and methods of use |
| WO2005002546A1 (fr) * | 2003-06-27 | 2005-01-13 | Smithkline Beecham Corporation | Compositions liposomales stabilisee de topotecane et procedes |
| JPWO2008026310A1 (ja) * | 2006-08-29 | 2010-01-14 | 株式会社セレックス | トレハロース含有口腔粘膜保護剤 |
| ES2657686T3 (es) | 2009-06-24 | 2018-03-06 | Lipoid Gmbh | Composición para aplicaciones cosméticas, farmacéuticas o dietéticas |
| SI2768484T1 (sl) | 2011-10-21 | 2019-12-31 | Jazz Pharmaceuticals Research Llc | Liofilizirani liposomi |
| US10448631B2 (en) | 2015-09-22 | 2019-10-22 | East Carolina University | Cryopreservation using sucralose |
| EP3813788A1 (fr) | 2018-06-27 | 2021-05-05 | Breath Therapeutics GmbH | Compositions pharmaceutiques sous forme lyophilisée |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH621479A5 (fr) * | 1977-08-05 | 1981-02-13 | Battelle Memorial Institute | |
| CA1173360A (fr) * | 1979-06-22 | 1984-08-28 | Jurg Schrank | Produits pharmaceutiques |
| DE3374837D1 (en) * | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| US4515736A (en) * | 1983-05-12 | 1985-05-07 | The Regents Of The University Of California | Method for encapsulating materials into liposomes |
| GB8407557D0 (en) * | 1984-03-23 | 1984-05-02 | Hayward J A | Polymeric lipsomes |
| US4880635B1 (en) * | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
-
1986
- 1986-01-08 EP EP19860900891 patent/EP0208764A4/fr not_active Withdrawn
- 1986-01-08 WO PCT/US1986/000016 patent/WO1986003938A1/fr not_active Application Discontinuation
- 1986-01-08 AU AU53183/86A patent/AU587600B2/en not_active Expired
- 1986-01-08 JP JP61500642A patent/JPS62501631A/ja active Pending
- 1986-01-09 CA CA000499252A patent/CA1275248C/fr not_active Expired - Lifetime
- 1986-09-08 DK DK198604283A patent/DK175799B1/da not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JPS62501631A (ja) | 1987-07-02 |
| AU5318386A (en) | 1986-07-29 |
| DK428386A (da) | 1986-11-11 |
| AU587600B2 (en) | 1989-08-24 |
| EP0208764A1 (fr) | 1987-01-21 |
| CA1275248C (fr) | 1990-10-16 |
| DK428386D0 (da) | 1986-09-08 |
| EP0208764A4 (fr) | 1987-10-08 |
| WO1986003938A1 (fr) | 1986-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK175799B1 (da) | Fremgangsmåde til præservering og fremgangsmåde til fremstilling af liposomer samt en lyophiliseret sammensætning og en præserveret sammensætning | |
| KR920002300B1 (ko) | 리포좀의 보존방법 | |
| US4857319A (en) | Method for preserving liposomes | |
| JP2574999B2 (ja) | 脱水リポソーム医薬製剤 | |
| US10835492B2 (en) | Method of lyophilizing liposomes | |
| US5077056A (en) | Encapsulation of antineoplastic agents in liposomes | |
| EP0437479B1 (fr) | Procede de fabrication de liposomes a stabilite amelioree pendant le sechage | |
| Meyer et al. | Efficient encapsulation of proteins within liposomes for slow release in vivo | |
| KR20000075479A (ko) | 물에 난용성인 활성성분이 캡슐화 되어 있는 동결 건조된 리포솜들을 함유하는 약학적 제제 및 그 제제의 제조공정 | |
| KR101209496B1 (ko) | 나노입자 제제를 보관하는 방법 | |
| JP2007511505A (ja) | リポソームにおける薬剤充填法 | |
| AU1361988A (en) | Dehydrating vesicule preparations for long-term storage | |
| CA1330199C (fr) | Vesiculation spontanee de liposomes multilamellaires | |
| Wasankar et al. | Liposome as a drug delivery system-a review | |
| Aoki et al. | High-efficiency entrapment of superoxide dismutase into cationic liposomes containing synthetic aminoglycolipid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUP | Patent expired |